IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC's Cannabis-based Eating Disorder Treatment Anticipated for PCT Filing in February

India Globalization Capital (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, has recently developed IGC-506 for the treatment of multiple types of eating disorders in humans, as well as animals in the veterinary market. The company expects to file a Patent Cooperation Treaty (“PCT”) application by February 28, 2018. PCT is an international patent filing effective in numerous foreign countries. An article discussing this reads: “IGC-506 is a combination therapy drug, developed from cannabis-extracts and other compounds, designed to treat multiple types of eating disorders. Cannabinoids are chemical compounds that exert a range of effects on the body. The non-psychoactive phytocannabinoid, cannabidiol (CBD), influences many pathways in humans, as well as cats and dogs, and may be used to provide relief for numerous symptoms ranging from pain to eating disorders.”

To view the full article, visit http://nnw.fm/u2Z0N

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.IGCInc.us.